Test directory: Keppra (Levetiracetam)

Ordering Code7990
Test NameKeppra (Levetiracetam)
AliasLevetiracetam
Keppra
Preferred SpecimenSerum
Preferred ContainerPlain (Red)
Optimum Volume1 mL
Collection InstructionsA steady state, trough (pre-dose) sample is generally accepted as most consistent for therapeutic drug monitoring of Levetiracetam

Brivaracetam (Briviact) interferes with this assay.
Handling InstructionsCentrifuge and separate within 2 hours of collection.
Transport RequirementsOahu: Refrigerated
Airline: Refrigerated
Specimen StabilityAmbient: Not Stable
Refrigerated: 1 Week
Frozen: 4 Weeks
Rejection CriteriaGel barrier tube, SST specimens unacceptable
Avail. StatNO
Analytic Time1-2 Days
MethodologyQuantitative Enzyme Immunoassay
Reference Lab Clinical Laboratories of Hi

Reference range(s)

The reference ranges listed below are valid on this date of April 27, 2024.
ComponentAgeMale NormMale Critical LowMale Critical HighFemale NormFemale Critical HighFemale Critical LowUnitsAdd'l info
Keppra LevelALL12.0-46.012.0-46.0mcg/mL

The reference...
The reference range for levetiracetam has not been well established. Therapeutic benefit may be achieved with serum drug concentrations outside of these ranges and toxicity may occur at levels below the reference range. The reference range reflects trough serum concentrations drawn just prior to the next dosage

Brivaracetam (Briviact) interferes with measurements of levetiracetam (Keppra) using this assay. Patients undergoing a switch in drug therapy involving Keppra and Briviact should not be monitored for levetiracetam using this assay
Serum levels of levetiracetam and/or brivaracetam should be confirmed by a valid chromatographic method if there is a possibility these drugs are co-present in circulation
Note1

Note1:


The reference range for levetiracetam has not been well established. Therapeutic benefit may be achieved with serum drug concentrations outside of these ranges and toxicity may occur at levels below the reference range. The reference range reflects trough serum concentrations drawn just prior to the next dosage

Brivaracetam (Briviact) interferes with measurements of levetiracetam (Keppra) using this assay. Patients undergoing a switch in drug therapy involving Keppra and Briviact should not be monitored for levetiracetam using this assay
Serum levels of levetiracetam and/or brivaracetam should be confirmed by a valid chromatographic method if there is a possibility these drugs are co-present in circulation
.